RT Journal Article
SR Electronic
T1 Genome-wide association study identifies five risk loci for pernicious anemia and implicates the role of HLA-DR15 haplotype
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.13.20211912
DO 10.1101/2020.10.13.20211912
A1 Triin Laisk
A1 Maarja Lepamets
A1 Reedik Mägi
YR 2020
UL http://medrxiv.org/content/early/2020/10/14/2020.10.13.20211912.abstract
AB Pernicious anemia is a rare condition characterized by vitamin B12 deficiency anemia due to lack of intrinsic factor, often caused by autoimmune gastritis. Patients with pernicious anemia have a higher incidence of other autoimmune disorders, such as type 1 diabetes, vitiligo and autoimmune thyroid issues. Therefore, the disease has a clear autoimmune basis, although the genetic susceptibility factors have thus far remained poorly studied. We conducted a genome-wide association study meta-analysis in 2,166 cases and 659,516 European controls from population-based biobanks and identified genome-wide significant signals in or near the PTPN22 (rs6679677, p=1.91 ⨯ 10−24, OR=1.63), PNPT1 (rs12616502, p=3.14 ⨯ 10−8, OR=1.70), HLA-DQB1 (rs28414666, p=1.40 ⨯ 10−16, OR=1.38), IL2RA (rs2476491, p=1.90 ⨯ 10−8, OR=1.22) and AIRE (rs74203920, p=2.33 ⨯ 10−9, OR=1.83) genes, thus providing the first robust associations between pernicious anemia and genetic risk factors. We further mapped the susceptibility in the HLA region to the HLA-DR15 haplotype. Analysis of associated diagnoses and disease trajectories confirm the association between pernicious anemia and thyroid issues, vitiligo, gastritis, stomach cancer, osteoporosis and other diagnoses.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementTL is supported by the Estonian Research Council grant MOBTP155. ML and RM are supported by the Estonian Research Council grant PRG687. Computations were performed in the High Performance Computing Center, University of Tartu.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Analysis in the Estonian Biobank was carried out under ethical approval 1.1-12/624 from the Estonian Committee on Bioethics and Human Research and data release N05 from the Estonian Biobank.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUsed UKBB and FinnGen summary statistics can be browsed and downloaded from UKBB PheWeb and FinnGen PheWeb, respectively. Full meta-analysis summary statistics will be made available upon publication. The analyses in this manuscript also included data from the Mouse Genome Database and the GTEx Portal. http://pheweb.sph.umich.edu/SAIGE-UKB/about http://r3.finngen.fi http://www.informatics.jax.org https://www.ebi.ac.uk/eqtl/